Form 4: Iovance Biotherapeutics Executive Frederick G. Vogt Reports Stock Transactions
SEC Form 4 Filing
Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On June 3, 2024, Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, had 10,417 restricted stock units (RSUs) vest.
- The company withheld 4,426 shares to satisfy tax obligations at a price of $8.37 per share.
- Following these transactions, Vogt directly owns 147,325 shares of common stock and 72,921 restricted stock units.
- The remaining RSUs will vest in equal quarterly installments.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions by an executive, with no inherent positive or negative implications for the company's performance.
Future Outlook
The remaining RSUs will vest in equal quarterly installments.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Key Dates
| Date | Description |
|---|---|
| 03/02/2023 | Date of grant for the reported RSUs |
| 06/03/2024 | Date of transaction: vesting of RSUs and tax withholding |
| 06/05/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.